AMEX
1.32USD
-0.01 (-0.38%)
We have scored 9 news catalysts on MAIA Biotechnology, Inc. (MAIA) over the past 12 months. The biggest single-day move next to one of them came Dec 11, 2025, when MAIA closed +18.8%: “MAIA's Ateganosine Surges Ahead with Breakthrough Momentum as Pivotal Phase 3 Trial Initiates”. Coverage across the window leans positive (average ticker sentiment +0.66). Most of the impact sits in price momentum and short squeeze potential.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
80.3M
P/E
—
EPS
—
Beta
0.26
52W range
0.87-3.19
Day range
1.31–1.33
Open
1.32
Prev close
1.33
Volume
222.7K
Avg volume
629K
Dividend
0.00
IPO
2022-07-28
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about MAIA Biotechnology, Inc. — not a sector bucket. Click an edge to see the articles that established the link.
Latest scored catalyst for MAIA: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
MAIA Biotechnology, Inc. is a clinical-stage biotech firm dedicated to discovering, developing, and commercializing treatments for various cancers, with a primary focus on non-small cell lung cancer. The company's leading experimental compound, THIO, is an investigational drug candidate that utilizes a unique dual mechanism by targeting telomeres and stimulating an immune response. Established in 2018, the enterprise maintains its headquarters in Chicago, Illinois.
